ARMP Armata Year-over-year earnings per share growth for the last twelve months

Official company branding of Armata Pharmaceuticals, Inc. (ARMP)

Full capacity utilization of phage synthesis laboratories is driving growth, as evidenced by this GURU.Markets chart: quarterly EPS dynamics are currently 68.30 hitting a new level. The business potential is based on the sale of treatments against superbugs. Furthermore, intellectual capital and patents for rare drugs create a solid foundation for the future monetization of Armata Pharmaceuticals (ARMP).

armatapharma.com (ARMP) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/15/2026

Analytical breakdowns for Armata Pharmaceuticals

- share price and expert price forecast:
Stock Price Armata|ARMP - Consensus Target
- market capitalization data:
Market Value Armata Pharmaceuticals, Inc.|ARMP - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Armata Pharmaceuticals|ARMP - Total Stockholders' Equity|Market Capitalization to Book Value Ratio armatapharma.com|ARMP - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Capital Armata Pharmaceuticals|ARMP - Long-Term Liabilities to Capital|Short-Term Debt to Equity Armata Pharmaceuticals Inc|ARMP - Company Total Debt Obligations|Debts to Book Capitalization Armata|ARMP - Company Long-Term Debts|Company Short-Term Debt Armata Pharmaceuticals|Quick Liquidity armatapharma.com
- earnings and market multiples details:
ARMP - Net Income|Projected Future Earnings Armata Pharmaceuticals|ARMP - P/E Multiple|Projected Price to Earnings Armata Pharma|ARMP - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Armata|ARMP - Operating profit EBITDA|Net earnings per share for the last 12 months Armata Pharmaceuticals|ARMP - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months armatapharma.com|ARMP - Earnings per share trend in current year|Earnings growth forecast for next year Armata Pharmaceuticals
- sales volume and revenue indicators:
ARMP - Company Sales Revenue|Projected Sales Volume Armata Pharmaceuticals Inc|ARMP - P/S Multiple|Price-to-Projected Revenue Ratio Armata Pharmaceuticals, Inc.
Analysis of all company metrics:Armata Pharmaceuticals Inc - ARMP
Flagship merchandise of Armata Pharmaceuticals

Quarterly EPS growth measures the dynamics of net profit per share, allowing for an assessment of business efficiency compared to previous periods. This metric calculates the percentage change in earnings, filtering out market noise from actual financial results. The current quarterly EPS variability is 68.30. For Armata Pharmaceuticals (ARMP), this indicator is critical as it reflects the cost of developing phage-based drugs. High FDA certification costs render profits volatile until clinical trials are completed.

Competitor analysis

ACXP: Quarterly EPS earnings growth